Just saw Organon announced some solid Phase 3 data on VTAMA cream for pediatric atopic dermatitis — basically showing kids are actually sleeping better after treatment. That's pretty significant because sleep disruption is honestly one of the worst parts of dealing with atopic dermatitis, especially for families.

The trial included over 650 kids aged 2-17 with moderate-to-severe atopic dermatitis, and they saw improvements in sleep outcomes as early as week one in some age groups. The fact that it works consistently across different age ranges, including kids as young as two years, is what caught my attention. FDA already approved it back in December, so this isn't theoretical anymore.

What's interesting is how the market's reacting — OGN stock only moved 0.8% despite the positive data. Meanwhile, the broader atopic dermatitis drug market is supposedly worth $17.21 billion and growing at 7.7% annually through 2032. You'd think strong efficacy data on a condition affecting so many kids would generate more momentum, but maybe investors are waiting for prescription adoption numbers. Either way, quality-of-life improvements like better sleep are exactly what patients and doctors actually care about with atopic dermatitis treatment.